Trial shows BD balloon compares well with angioplasty for CLI

This article was originally published here

Becton DickinsonBD (NYSE: BDX) today touted the results of a clinical trial that showed “statistically significant safety equivalence” between its Lutonix 014 drug-coated balloon (DCB) and a standard angioplasty catheter (PTA) in treating narrowed or obstructed arteries below the knee.

The trial’s primary safety endpoint—freedom from composite all-cause death, above the ankle or major reintervention of the treated limb through 30 days—was met in both the proportional and binary and Kaplan Meier analyses of patient survival following a medical procedure. BD presented the trial results during a late-breaking clinical trials session at the Vascular Interventional Advances (VIVA) conference in Las Vegas.

Get the full story on our sister site, Medical Design & Outsourcing.

The post Trial shows BD balloon compares well with angioplasty for CLI appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply